Brief: Chromadex Corp Reports Fourth Quarter and Fiscal Year 2022 Results

Niagen Bioscience

08/03/2023 21:04

March 8 (Reuters) - Chromadex Corp  CDXC.O :
    * ORATION REPORTS FOURTH QUARTER AND FISCAL YEAR 2022
RESULTS
    * Q4 SALES ROSE 18 PERCENT TO $21.0 MILLION
    * Q4 LOSS PER SHARE $0.02
    * FOR FULL YEAR 2023, CO EXPECTS AT LEAST 10% REVENUE GROWTH
    * Q4 EARNINGS PER SHARE VIEW $-0.02, REVENUE VIEW $21.1
MILLION --
REFINITIV IBES DATA

Source text for Eikon:  ID:nBw71YYkxa 
Further company coverage:  CDXC.O 

 ((Reuters.Briefs@thomsonreuters.com;))